Josh Gottheimer, U.S. Representative

Josh Gottheimer

DemocratNJ05houseFiled Jul 16, 2025

Josh Gottheimer (D-NJ) sold $1K-$15K of $AKAM (Akamai Technologies, Inc. - Common Stock) on Jun 3, 2025, part of 18 transactions in this filing (6 buys, 12 sells).

HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.

Transactions
18
Companies
15
Largest Trade
$1K-$15K
Timing Flags
5

Companies in this filing · 15

Price Movement Since Trade

How the largest positions have moved from the trade date to the most recent close.

Showing the 6 largest positions. See every transaction in the table below.

Suspicious Timing Detected

5 flags
1.

Josh Gottheimer sold $1,001 - $15,000 in $PFE on 2025-06-03, 2 days before the 'Treat and Reduce Obesity Act of 2025' (S1973) was introduced, which aims to expand Medicare coverage for obesity treatments.

2.

Josh Gottheimer sold $1,001 - $15,000 in $PFE on 2025-06-03, 8 days before the 'Medical Research for Our Troops Act' (HR3906) was introduced, proposing to restore $1.181 billion to the Defense Health Agency for military health R&D.

3.

Josh Gottheimer sold $1,001 - $15,000 in $TSLA on 2025-06-05, 40 days before the 'STOP China Act' (HR4361) was introduced, which aims to prohibit federal funds for vehicles and vehicle technologies from Chinese entities.

4.

Josh Gottheimer sold $1,001 - $15,000 in $TSLA on 2025-06-05, 42 days before the 'Price Gouging Prevention Act of 2025' (HR4528) was introduced, which directly limits corporate profitability for large-cap companies.

5.

Josh Gottheimer sold $1,001 - $15,000 in $CRM on 2025-06-04, 47 days before the 'AI Accountability and Personal Data Protection Act' (S2367) was introduced, which introduces a Federal tort for data exploitation.

These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.

Share This Filing

All Transactions

BUY$1K-$15K
$AVGOBroadcom Inc. - Common Stock
$264.65 \u2192 N/A
Jun 25, 2025 \u2022 joint
BUY$1K-$15K
$CVNACarvana Co. Class A Common Stock
Jun 20, 2025 \u2022 joint
BUY$1K-$15K
$CBChubb Limited Common Stock
$286.79 \u2192 N/A
Jun 13, 2025 \u2022 joint
BUY$1K-$15K
$NETCloudflare, Inc. Class A Common Stock
Jun 20, 2025 \u2022 joint
BUY$1K-$15K
$INSMInsmed Incorporated - Common Stock
Jun 16, 2025 \u2022 joint
BUY$1K-$15K
$NVDANVIDIA Corporation - Common Stock
$147.90 \u2192 N/A
Jun 24, 2025 \u2022 joint
SELL$1K-$15K
$AKAMAkamai Technologies, Inc. - Common Stock
$77.09 \u2192 N/A
Jun 3, 2025 \u2022 joint
PARTIAL SELL$1K-$15K
$COPConocoPhillips Common Stock
$89.39 \u2192 N/A
Jun 24, 2025 \u2022 joint
SELL$1K-$15K
$FISFidelity National Information Services, Inc. Common Stock
$80.14 \u2192 N/A
Jun 3, 2025 \u2022 joint
PARTIAL SELL$1K-$15K
$MCDMcDonald's Corporation Common Stock
$287.46 \u2192 N/A
Jun 20, 2025 \u2022 joint

Connected Legislative Activity

10 signals

These bills and contracts share tickers or sectors with this filing's trades.

BillS1973bullish

Treat and Reduce Obesity Act of 2025

The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.

Jun 5, 2025
LLYNVO
BillHR4361neutral

STOP China Act

The STOP China Act (HR4361) is an early-stage bill restricting federal funds for vehicles from Chinese entities. With only 2 cosponsors and referral to committee, this is a low-probability legislative event with no near-term market impact. Real market data shows no correlation — OSK up 3.82% in 7 days, GM down 0.45%, Ford down 4.93% — driven by broader auto sector dynamics, not this bill.

Jul 15, 2025
BillHR4668bearish

End the Vaccine Carveout Act

The End the Vaccine Carveout Act (HR 4668) is an early-stage bill with 29 cosponsors that would eliminate the PREP Act liability shield for vaccine manufacturers, exposing $PFE, $MRNA, $GSK, and $JNJ to direct civil lawsuits for vaccine-related injuries. The bill has no near-term passage probability — it was referred to committee in July 2025 with zero further action — but its reintroduction signals continued legislative risk for the vaccine liability framework. Real market data shows all four tickers are down over the trailing 30 days ($PFE -5.09%, $MRNA -7.03%, $GSK -5.16%, $JNJ -5.87%), consistent with broader pharma weakness rather than a discrete bill-event reaction.

Jul 23, 2025
GSKMRNAPFE
Billneutral

BLUE TECH INC.: $15.6M Department of Homeland Security Contract

This $15.6 million contract for Salesforce software licenses to BLUE TECH INC. will indirectly benefit Salesforce ($CRM) as the primary software provider, representing a routine but consistent revenue stream for the company.

Sep 19, 2025
AMZNCRMCRWDMSFTZS
BillHR3906neutral

Medical Research for Our Troops Act

HR3906 (Medical Research for Our Troops Act) would restore $1.181B in military medical research funding, but the bill has been stalled in the House Appropriations Committee since June 2025 with zero legislative movement. Real market data shows healthcare stocks declining 3-8% over 30 days due to broader sector headwinds, not this bill. No actionable trade signal exists.

Jun 11, 2025
BillHR4528bearish

Price Gouging Prevention Act of 2025

The Price Gouging Prevention Act of 2025 (HR4528) is an early-stage House bill capping corporate margins during 'exceptional market shocks'. Currently referred to committee with zero appropriations, the bill poses a structural long-term regulatory risk to all large-cap companies with pricing flexibility, particularly retailers ($WMT, $AMZN) and integrated energy ($XOM, $CVX). Near-term market impact is low given early legislative stage, but the bill's breadth — covering all goods and services — represents a significant expansion of FTC authority if it advances.

Jul 17, 2025
AMZNCVXJNJPFETSLAWMT
BillS2367bearish

AI Accountability and Personal Data Protection Act

S.2367 introduces a broad federal tort for personal data exploitation without express consent, directly targeting the data practices underlying AI training and advertising at META, GOOGL, AMZN, MSFT, and CRM. The bill is early-stage (introduced July 2025, referred to Judiciary Committee), but its language is aggressive and unambiguous. Current market prices show a sharp 1-day drop for META (-8.72% 7-day) and GOOGL at an all-time high of $373.96 — divergence suggests GOOGL's run is driven by other factors, not immunity from this risk.

Jul 21, 2025
AMZNCRMGOOGLMETAMSFT
BillS2857neutral

Protecting Free Vaccines Act of 2025

The Protecting Free Vaccines Act of 2025 is an early-stage bill (S.2857) that codifies existing ACIP vaccine coverage mandates through 2030 without expanding coverage, creating new funding, or changing market dynamics. The bill's impact on vaccine manufacturers and insurers is neutral: it removes regulatory uncertainty but provides no growth catalyst. All S&P 500 stocks covered have been declining over the past 30 days, with MRNA down 13.49% in the last week alone. This bill does not alter those trends.

Sep 18, 2025
CVSJNJMRNAPFEUNH
BillHR4548bullish

Small Nonprofit Retirement Security Act of 2025

HR4548 opens the tax-exempt small employer market (1.3M 501(c) organizations) to retirement plan subsidies for the first time, creating a new customer acquisition opportunity for payroll and retirement administration providers ADP and PAYX. The bill is in early legislative stages with bipartisan sponsorship.

Jul 21, 2025
ADPPAYX
BillHR5448bullish

Protecting Free Vaccines Act

The Protecting Free Vaccines Act (HR5448) is an early-stage House bill that would mandate zero-cost-sharing coverage for ACIP-recommended vaccines across Medicare, Medicaid, CHIP, and private insurance until 2030. Vaccine manufacturers like Pfizer and Moderna are structurally positioned to benefit from increased utilization, while health insurers like UnitedHealth face higher claims costs. CVS has mixed exposure as both insurer (Aetna) and vaccine administrator (CVS Pharmacy). The bill is referred to three committees with 72 cosponsors and has a Senate companion bill (S2857), but a long legislative path remains.

Sep 18, 2025
CVSMRNAPFEUNH

Other Filings by Josh Gottheimer

Free — no credit card

Get the next Gottheimer trade the day it's disclosed

HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →

Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.